3 Finished Dosage Generics Maker, Leading FMCG Company and Cement and Building Products Maker Stocks With a Strong Future Roadmap: Strides Pharma Science, Hindustan Unilever and JK Cement
- November 5, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
Strides Pharma Science, Hindustan Unilever and JK Cement: ROE of 14.1% to 22.4% and FY22 to FY26 revenue CAGR of 5.5% to 14.4%. Prices as of 4 Nov 2026.
Quick Answer
The three generic drug, daily essentials and cement stocks to watch are Strides Pharma Science, Hindustan Unilever and JK Cement. Their return on equity ranges from 14.1% to 22.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.5% to 14.4%. Hindustan Unilever has the highest return on equity at 22.4%, while JK Cement has the fastest revenue growth at 14.4% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Generic drug, daily essentials and cement stocks bring together companies with a visible plan for the years ahead. Strides Pharma Science, Hindustan Unilever and JK Cement cover a finished dosage generics maker, a leading FMCG company and a cement maker.
This list covers three generic drug, daily essentials and cement stocks with complete current figures: Strides Pharma Science, Hindustan Unilever and JK Cement. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic Drug, Daily Essentials and Cement Stocks?
Generic drug, daily essentials and cement stocks are listed companies that make finished dosage generics, sell soaps, detergents, beverages and packaged foods across India, and produce cement and building products such as wall putty. Their earnings depend on drug approvals, household spending and construction activity.
Generic Drug, Daily Essentials and Cement Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Strides Pharma Science | 1,014.2 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Hindustan Unilever | 1,977.1 | 427,626 | 28.6 | 32.6 | 22.4 | 0.03 |
| JK Cement | 5,076.3 | 37,671 | 40.1 | 29.1 | 14.1 | 0.88 |
On valuation, Strides Pharma Science and Hindustan Unilever trade at a P/E below the industry P/E, while JK Cement trades above it, which reflects the growth the market already expects. Readers comparing generic drug, daily essentials and cement stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Generic Drug, Daily Essentials and Cement Stocks Have a Strong Roadmap in India?
Generic drug, daily essentials and cement stocks have a strong roadmap in India because steady demand for generics, resilient household spending and growing construction work keep widening the market for these companies.
- Generics. Regulated markets buy dependable supply.
- Daily essentials. Households buy trusted brands.
- Cement. Housing and roads need steady supply.
Why Strides Pharma Science Features Among These Generic Drug, Daily Essentials and Cement Stocks
Among the generic drug, daily essentials and cement stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Hindustan Unilever Features Among These Generic Drug, Daily Essentials and Cement Stocks
Among the pharma, FMCG and building shares on this list, Hindustan Unilever is India’s largest fast-moving consumer goods company, with brands across home care, beauty and personal care, foods and refreshment that reach households in every part of the country.
Revenue rose from Rs 52,704 crore in FY22 to Rs 65,219 crore in FY26, a compound annual growth rate of 5.5%. Net profit for FY26 was Rs 10,652 crore, a net margin of 16.3%.
In the June 2026 quarter, revenue grew 9.8% year on year to Rs 17,529 crore. The company has a return on equity of 22.4%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 427,626 crore. The stock trades at a P/E of 28.6, below the industry P/E of 32.6.
Roadmap: The company is premiumising its portfolio, expanding in newer categories and strengthening its rural and digital reach. A trusted brand portfolio supports steady volume growth.
What to watch: Track volume growth, rural demand and margin trends in the core categories.
Why JK Cement Features Among These Generic Drug, Daily Essentials and Cement Stocks
Among the three companies on this list, JK Cement is a cement and building products company with plants in northern, western and southern India. It sells grey cement, white cement and wall putty, and it has a strong presence in the premium white cement segment.
In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%.
Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1.
Roadmap: The company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.
What to watch: Track capacity additions, volume growth and realisation per tonne.
Strides Pharma Science vs Hindustan Unilever vs JK Cement on Key Financials
The table below sets the three generic drug, daily essentials and cement stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Hindustan Unilever | 52,704 | 65,219 | 5.5% | 10,652 | 16.3% |
| JK Cement | 8,134 | 13,917 | 14.4% | 988 | 7.1% |
Hindustan Unilever posts the highest return on equity in this group at 22.4%. Hindustan Unilever has the largest FY26 revenue at Rs 65,219 crore, and JK Cement shows the fastest revenue growth with a 14.4% compound annual rate. A useful habit with generic drug, daily essentials and cement stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
| Hindustan Unilever | 15,958 | 17,529 | 9.8% |
| JK Cement | 3,409 | 4,071 | 19.4% |
Key Risks to Check Before Investing in Generic Drug, Daily Essentials and Cement Stocks
Every theme carries risks that deserve a check before any decision. For these generic drug, daily essentials and cement stocks, the main points are: Long-term pharma, FMCG and building shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Housing cycles. Real estate and building demand can vary with rates and sentiment.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generic drug, daily essentials and cement stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generic Drug, Daily Essentials and Cement Stocks
Generic drug, daily essentials and cement stocks suit investors who prefer to study business strength before price moves. Strides Pharma Science, Hindustan Unilever and JK Cement each have a clear plan to grow. Based on the 4 November 2026 close, Strides Pharma Science trades at Rs 1,014.2, Hindustan Unilever at Rs 1,977.1 and JK Cement at Rs 5,076.3. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these generic drug, daily essentials and cement stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track generic drug, daily essentials and cement stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generic drug, daily essentials and cement stocks?
Ans. Generic drug, daily essentials and cement stocks are listed companies that make finished dosage generics, sell soaps, detergents, beverages and packaged foods across India, and produce cement and building products such as wall putty. Their earnings depend on drug approvals, household spending and construction activity. This list looks at three of them, Strides Pharma Science, Hindustan Unilever and JK Cement, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which generic drug, daily essentials and cement stocks are covered in this list?
Ans. This list covers Strides Pharma Science, Hindustan Unilever and JK Cement. Based on the 4 November 2026 close, Strides Pharma Science traded at Rs 1,014.2, Hindustan Unilever at Rs 1,977.1 and JK Cement at Rs 5,076.3. Their return on equity ranges from 14.1% to 22.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.5% to 14.4%.
Why do generic drug, daily essentials and cement stocks have a strong future roadmap in India?
Ans. Generic drug, daily essentials and cement stocks have a strong roadmap in India because steady demand for generics, resilient household spending and growing construction work keep widening the market for these companies. The main drivers are as follows. Generics. Regulated markets buy dependable supply. Daily essentials. Households buy trusted brands. Cement. Housing and roads need steady supply. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Hindustan Unilever performed financially?
Ans. Revenue rose from Rs 52,704 crore in FY22 to Rs 65,219 crore in FY26, a compound annual growth rate of 5.5%. Net profit for FY26 was Rs 10,652 crore, a net margin of 16.3%. In the June 2026 quarter, revenue grew 9.8% year on year to Rs 17,529 crore. The company has a return on equity of 22.4%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 427,626 crore. The stock trades at a P/E of 28.6, below the industry P/E of 32.6. Looking ahead, the company is premiumising its portfolio, expanding in newer categories and strengthening its rural and digital reach. A trusted brand portfolio supports steady volume growth.
How has JK Cement performed financially?
Ans. Revenue rose from Rs 8,134 crore in FY22 to Rs 13,917 crore in FY26, a compound annual growth rate of 14.4%. Net profit grew from Rs 679 crore in FY22 to Rs 988 crore in FY26, which works out to a compound annual growth rate of 9.8%. In the June 2026 quarter, revenue grew 19.4% year on year to Rs 4,071 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.88 and a market capitalisation of Rs 37,671 crore. The stock trades at a P/E of 40.1, above the industry P/E of 29.1. Looking ahead, the company is expanding grey cement capacity in several regions and growing its white cement and putty range, which carries a strong brand. Housing and infrastructure activity supports steady cement demand.
What risks should investors check before buying generic drug, daily essentials and cement stocks?
Ans. Investors should check a few risks before buying generic drug, daily essentials and cement stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Housing cycles. Real estate and building demand can vary with rates and sentiment. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generic drug, daily essentials and cement stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.